16.64
0.83%
-0.14
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
Data di fine periodo | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
Revenues |
7.79%
167.12
|
181.24 | 163.93 | 169.47 | 160.34 |
Cost Of Revenue |
0.58%
47.42
|
47.69 | 39.75 | 48.21 | 49.02 |
Gross Profit |
10.37%
119.70
|
133.55 | 124.18 | 121.26 | 111.32 |
Operating Expenses
|
6.08%
106.49
|
100.38 | 106.45 | 81.38 | 114.41 |
Interest Income/Expense |
2.13%
3.316
|
3.388 | 3.464 | 3.865 | 9.589 |
Benefits Costs and Expenses |
4.04%
153.48
|
147.52 | 147.32 | 131.61 | 186.81 |
Costs And Expenses |
3.94%
153.91
|
148.08 | 146.21 | 129.59 | 163.43 |
Operating Income/Loss |
60.17%
13.21
|
33.17 | 17.72 | 39.88 | -3.091 |
Nonoperating Income/Loss |
22.46%
0.428
|
0.552 | -1.12 | -2.023 | -23.38 |
Income/Loss From Continuing Operations Before Tax |
59.55%
13.64
|
33.72 | 16.60 | 37.85 | -26.47 |
Income Tax Expense/Benefit, Deferred |
47.54%
3.463
|
6.601 | 4.914 | 11.44 | -7.342 |
Income Tax Expense/Benefit |
47.33%
4.661
|
8.85 | 5.743 | 12.09 | -6.938 |
Income/Loss From Continuing Operations After Tax |
63.90%
8.979
|
24.87 | 10.86 | 25.76 | -19.54 |
Net Income/Loss
|
63.90%
8.979
|
24.87 | 10.86 | 25.76 | -19.54 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
65,392%
46.50
|
0.071 | 46.42 | 46.09 | 45.95 |
Diluted Average Shares |
826.06%
52.19
|
5.636 | 52.07 | 52.05 | 45.95 |
Basic Earnings Per Share |
64.81%
0.19
|
0.54 | 0.23 | 0.56 | -0.43 |
Diluted Earnings Per Share |
63.46%
0.19
|
0.52 | 0.23 | 0.51 | -0.43 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):